Trial-Results center  
Clinical trial results database in Heart and vessels Feedback    Home

Systematic review and meta-analysis

This trial is included in the following systematic reviews and meta-analyses:

cardiovascular prevention - CEPT inhibition - all type of patients

cardiovascular prevention - HDL increasing drugs - all type of patients


Related trials

ACCELERATE, 2015 - evacetrapib vs placebo

dal-OUTCOMES, 2012 - dalcetrapib vs placebo

AIM-HIGH, 2011 - niacin vs placebo (on top statin)

dal-VESSEL, 2011 - dalcetrapib vs placebo

ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)

DEFINE, 2010 - anacetrapib vs placebo

Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)

Emmerich, 2009 - etofibrate vs placebo

ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe

ARBITER 2, 2009 - niacin vs placebo (on top statin)

ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

RADIANCE 1, 2007 - torcetrapib vs placebo (on top of atorvastatin)

ILLUSTRATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)

RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)

FIELD, 2005 - fenofibrate vs placebo

LEADER, 2002 - bezafibrate vs placebo

DAIS, 2001 - fenofibrate vs placebo

HATS, 2001 - niacin vs placebo (on top statin)

BIP, 2000 - bezafibrate vs placebo

VA-HIT, 1999 - gemfibrozil vs placebo

SENDCAP, 1998 - bezafibrate vs placebo

LOCAT, 1997 - gemfibrozil vs placebo

BECAIT, 1996 - bezafibrate vs placebo

HHS (Frick)(secondary prev subgroup), 1993 - gemfibrozil vs placebo

Hanefeld, 1991 - clofibrate vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All clinical trials of HDL increasing drugs
  • All clinical trials of torcetrapib
    		•  
     ILLUMINATE study, 2007 TRC9362 
    [NCT00134264] download pdf: torcetrapib | CEPT inhibition for cardiovascular prevention

    Treatments

    Studied treatment torcetrapib 60mg daily plus atorvastatin (at a dose established during the runin period)
    Control treatment atorvastatin alone

    Patients

    Patients patients at high cardiovascular risk

    Method and design

    Randomized effectives 7533 / 7534 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 1.52y
    Number of centre 260
    Geographic area 7 countries
    Primary endpoint MACE


    Results



    Endpoints and data reported in the trial's publication(s)

    Endpoint Events (%) Relative Risk 95% CI
    Studied treat. Control treat.
    Primary composite outcome 464 / 7533 (6,2%) 373 / 7534 (5,0%) 1,24 [1,09;1,42]
    Death from coronary heart disease 40 / 7533 (0,5%) 33 / 7534 (0,4%) 1,21 [0,77;1,92]
    Nonfatal myocardial infarction 142 / 7533 (1,9%) 118 / 7534 (1,6%) 1,20 [0,94;1,53]
    Stroke 43 / 7533 (0,6%) 40 / 7534 (0,5%) 1,08 [0,70;1,65]
    Hospitalization for unstable angina 270 / 7533 (3,6%) 201 / 7534 (2,7%) 1,34 [1,12;1,61]
    Death from any cause 93 / 7533 (1,2%) 59 / 7534 (0,8%) 1,58 [1,14;2,18]
    Composite of death from coronary heart disease, nonfatal myocardial infarction, and stroke� 214 / 7533 (2,8%) 185 / 7534 (2,5%) 1,16 [0,95;1,40]
    Hemorrhagic Stroke 5 / 7533 (0,1%) 2 / 7534 (0,0%) 2,50 [0,49;12,88]
    Ischemic Stroke 31 / 7533 (0,4%) 30 / 7534 (0,4%) 1,03 [0,63;1,71]
    Embolic Stroke 7 / 7533 (0,1%) 9 / 7534 (0,1%) 0,78 [0,29;2,09]
    Not classified Stroke 0 / 7533 (0,0%) 0 / 7534 (0,0%) 1,00 [0,02;50,40]
    Coronary revascularization procedure 505 / 7533 (6,7%) 403 / 7534 (5,3%) 1,25 [1,10;1,42]
    Peripheral vascular disease� 110 / 7533 (1,5%) 159 / 7534 (2,1%) 0,69 [0,54;0,88]
    Transient ischemic attack 23 / 7533 (0,3%) 13 / 7534 (0,2%) 1,77 [0,90;3,49]
    Hospitalization with primary diagnosis of congestive heart failure 84 / 7533 (1,1%) 50 / 7534 (0,7%) 1,68 [1,19;2,38]
    Major coronary event 179 / 7533 (2,4%) 147 / 7534 (2,0%) 1,22 [0,98;1,51]
    Major cardiovascular event and coronary revascularization procedure 738 / 7533 (9,8%) 589 / 7534 (7,8%) 1,25 [1,13;1,39]
    Major cardiovascular event, coronary revascularization pro-cedure, and peripheral vascular disease 820 / 7533 (10,9%) 723 / 7534 (9,6%) 1,13 [1,03;1,25]
    Stroke and transient ischemic attack 65 / 7533 (0,9%) 53 / 7534 (0,7%) 1,23 [0,85;1,76]
    Major coronary event, stroke, and transient ischemic attack 234 / 7533 (3,1%) 197 / 7534 (2,6%) 1,19 [0,99;1,43]
    Procedure-related myocardial infarction 11 / 7533 (0,1%) 8 / 7534 (0,1%) 1,38 [0,55;3,42]
    Any cardiovascular cause 49 / 7533 (0,7%) 35 / 7534 (0,5%) 1,40 [0,91;2,16]
    Sudden death 26 / 7533 (0,3%) 25 / 7534 (0,3%) 1,04 [0,60;1,80]
    Fatal myocardial infarction (not procedure-related) 8 / 7533 (0,1%) 6 / 7534 (0,1%) 1,33 [0,46;3,84]
    Hemorrhagic Fatal stroke 4 / 7533 (0,1%) 0 / 7534 (0,0%) 8,00 [0,42;151,32]
    Ischemic Fatal stroke 2 / 7533 (0,0%) 0 / 7534 (0,0%) 4,00 [0,18;88,70]
    Embolic Fatal stroke 0 / 7533 (0,0%) 0 / 7534 (0,0%) 1,00 [0,02;50,40]
    Not classified Fatal stroke 0 / 7533 (0,0%) 0 / 7534 (0,0%) 1,00 [0,02;50,40]
    Fatal heart failure 2 / 7533 (0,0%) 1 / 7534 (0,0%) 2,00 [0,18;22,06]
    Other vascular-related cause 1 / 7533 (0,0%) 2 / 7534 (0,0%) 0,50 [0,05;5,51]
    Fatal myocardial infarction (procedure-related) 2 / 7533 (0,0%) 0 / 7534 (0,0%) 4,00 [0,18;88,70]
    Other cardiac-related cause 4 / 7533 (0,1%) 1 / 7534 (0,0%) 4,00 [0,45;35,79]
    death from Any noncardiovascular cause 40 / 7533 (0,5%) 20 / 7534 (0,3%) 2,00 [1,17;3,42]
    death from Cancer 24 / 7533 (0,3%) 14 / 7534 (0,2%) 1,71 [0,89;3,31]
    death from Infection 9 / 7533 (0,1%) 0 / 7534 (0,0%) 18,00 [1,04;310,49]
    death from Trauma 3 / 7533 (0,0%) 3 / 7534 (0,0%) 1,00 [0,20;4,95]
    Suicide or homicide 0 / 7533 (0,0%) 1 / 7534 (0,0%) 0,50 [0,02;14,90]
    Odeath from ther cause 4 / 7533 (0,1%) 2 / 7534 (0,0%) 2,00 [0,37;10,92]
    Reason unknown death 4 / 7533 (0,1%) 4 / 7534 (0,1%) 1,00 [0,25;4,00]

    Endpoints used by the meta-analysis and data retained for this trial

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Coronary revascularization

    505 / 7533
         403 / 7534
         1,25 [1,10;1,42]

    stroke (fatal and non fatal)

    43 / 7533
         40 / 7534
         1,08 [0,70;1,65]

    Non fatal MI

    142 / 7533
         118 / 7534
         1,20 [0,94;1,53]

    Coronary event

    179 / 7533
         147 / 7534
         1,22 [0,98;1,51]

    Cardiovascular death

    49 / 7533
         35 / 7534
         classic 1,40 [0,91;2,16]

    All cause death

    93 / 7533
         59 / 7534
         classic 1,58 [1,14;2,18]

    cardiovascular events

    214 / 7533
         185 / 7534
         1,16 [0,95;1,40]

    Coronary death

    40 / 7533
         33 / 7534
         1,21 [0,77;1,92]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    All cause death 93 / 7533 (1,2%) 59 / 7534 (0,8%) 1,58 [1,14;2,18] Death from any cause 
    Non fatal MI 142 / 7533 (1,9%) 118 / 7534 (1,6%) 1,20 [0,94;1,53] Nonfatal myocardial infarction 
    cardiovascular events 214 / 7533 (2,8%) 185 / 7534 (2,5%) 1,16 [0,95;1,40] Composite of death from coronary heart disease, nonfatal myocardial infarction, and stroke� 
    Coronary death 40 / 7533 (0,5%) 33 / 7534 (0,4%) 1,21 [0,77;1,92] Death from coronary heart disease 
    Cardiovascular death 49 / 7533 (0,7%) 35 / 7534 (0,5%) 1,40 [0,91;2,16] Any cardiovascular cause 
    stroke (fatal and non fatal) 43 / 7533 (0,6%) 40 / 7534 (0,5%) 1,08 [0,70;1,65] Stroke 
    Coronary revascularization 505 / 7533 (6,7%) 403 / 7534 (5,3%) 1,25 [1,10;1,42] Coronary revascularization procedure 
    Coronary event 179 / 7533 (2,4%) 147 / 7534 (2,0%) 1,22 [0,98;1,51] Major coronary event 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction (for a follow-up of 1.52y)
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    All cause death 1,23% 7,83‰ 0,45%
    Non fatal MI 1,89% 1,57% 0,32%
    cardiovascular events 2,84% 2,46% 0,39%
    Coronary death 5,31‰ 4,38‰ 0,09%
    Cardiovascular death 6,50‰ 4,65‰ 0,19%
    stroke (fatal and non fatal) 5,71‰ 5,31‰ 0,04%
    Coronary revascularization 6,70% 5,35% 1,4%
    Coronary event 2,38% 1,95% 0,43%

    Meta-analysis of all similar trials:

    CEPT inhibition in cardiovascular prevention for all type of patients

    HDL increasing drugs in cardiovascular prevention for all type of patients



    Reference(s)

    TrialResults-center ID TRC9362
    Trials register # NCT00134264
    • Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events.. N Engl J Med 2007 Nov 22;357:2109-22 - 10.1056/NEJMoa0706628
      Pubmed | Hubmed | Fulltext

    (c) 2004-2016 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100Heart and vessels